An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

BACKGROUND: Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. METHODS: EGFR-TKI treatment-naïve patients with EGFR mutation-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Kim, Jin-Soo, Kim, Joo-Hang, Kim, Young-Chul, Kim, Hoon-Gu, Cho, Eun Kyung, Jin, Jong-Youl, Kim, Miyoung, Märten, Angela, Kang, Jin-Hyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274031/
https://www.ncbi.nlm.nih.gov/pubmed/34253172
http://dx.doi.org/10.1186/s12885-021-08445-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274031/
https://www.ncbi.nlm.nih.gov/pubmed/34253172
http://dx.doi.org/10.1186/s12885-021-08445-9

Ejemplares similares